咋了？这家农化巨头正在考虑，把自己卖了！

Core Viewpoint - FMC Corporation's board has approved the exploration of various strategic options, including the potential sale of the company, amid financial challenges and declining revenues [1][3]. Financial Performance - FMC reported a revenue of $3.47 billion for 2025, a decrease of 18% compared to 2024, primarily due to a 6% drop in product prices [1][3]. - The company experienced a net loss of $2.24 billion for the year, which is a reduction of $2.58 billion from the previous year [1][3]. - For 2026, FMC expects revenues to be between $3.6 billion and $3.8 billion, reflecting a 5% decline year-over-year [5]. Strategic Challenges - The expiration of the patent for the pesticide Rynaxypyr has posed strategic and operational challenges for FMC [1][3]. - The company is implementing a 2026 operational plan that includes asset sales and licensing agreements to repay $1 billion in debt, aiming to optimize its balance sheet [1][3]. Market Conditions - FMC faces ongoing debt issues and has seen its credit rating downgraded from BBB- to BB+ by S&P Global Ratings, indicating a non-investment grade status [2][4]. - The company is under pressure from generic competition, particularly in Latin America and Asia, which may impact pricing and profit margins [2][4]. - FMC is also contending with weak agricultural demand and competition from lower-priced products offered by rivals [2][4]. Future Outlook - FMC's CEO, Pierre Brondeau, emphasized that the focus for 2026 will be on executing operational plans to strengthen the balance sheet and enhance overall business competitiveness [2][4]. - The sales of new active ingredients are projected to be between $300 million and $400 million, with adjusted EBITDA expected to be between $670 million and $730 million, a 17% decline from the previous year [5].